Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
4.620
+0.170 (3.82%)
Jan 17, 2025, 4:00 PM EST - Market closed

Camp4 Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022
Period Ending
Sep '24 Dec '23 Dec '22
Revenue
-0.35-
Cost of Revenue
37.9339.0634.1
Gross Profit
-37.93-38.71-34.1
Selling, General & Admin
13.0511.6110.23
Research & Development
1.561.560.68
Operating Expenses
14.613.1710.91
Operating Income
-52.53-51.88-45
Interest & Investment Income
1.292.810.9
Other Non Operating Income (Expenses)
-0.26-0.22-0.1
Pretax Income
-51.5-49.29-44.19
Net Income
-51.5-49.29-44.19
Net Income to Common
-51.5-49.29-44.19
Shares Outstanding (Basic)
000
Shares Outstanding (Diluted)
000
Shares Change (YoY)
55.25%26.47%-
EPS (Basic)
-106.23-124.79-141.51
EPS (Diluted)
-106.23-124.79-141.51
Free Cash Flow
-46.48-44.83-42.57
Free Cash Flow Per Share
-95.86-113.51-136.31
Operating Margin
--14822.57%-
Profit Margin
--14083.14%-
Free Cash Flow Margin
--12809.43%-
EBITDA
-50.82-50.2-44.12
D&A For EBITDA
1.711.680.88
EBIT
-52.53-51.88-45
Source: S&P Capital IQ. Standard template. Financial Sources.